RT Journal Article
T1 Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases.
A1 Alcaide, Julia
A1 Delgado, Mayte
A1 Legerén, Marta
A1 Jurado, José Miguel
A1 Blancas, Isabel
A1 Pereda, Teresa
A1 López, Jorge
A1 Garrido, Margarita
A1 Sánchez, María J
A1 García, José L
A1 Rueda, Antonio
K1 Metastatic colorectal cancer
K1 Aflibercept
K1 Angiogenesis
K1 Targeted therapy
K1 VEGF
K1 VEGFR
K1 Camptotecina
K1 Neoplasias colorrectales
K1 Ensayos de Uso compasivo
K1 Supervivencia sin enfermedad
K1 Humanos
K1 Hipertensión
K1 Mutación
K1 Compuestos organoplatinos
K1 Poliésteres
K1 Proteinuria
K1 Proteínas recombinantes de fusión
K1 Receptores de Factores de crecimiento endotelial vascular
AB Aflibercept is a recombinant fusion protein that acts by inhibiting tumoural angiogenesis. Efficacy data obtained in the VELOUR randomised study has contributed to the approval of aflibercept as a second-line metastatic colorectal cancer (mCRC) treatment following an oxaliplatin-based regimen. The present study reports a case series of five patients with mCRC, who were treated in two centres since 2011 in the Compassionate Use Program for aflibercept. All patients had a KRAS mutation and previously received palliative fluoropyrimidine-oxaliplatin-based chemotherapy with bevacizumab. A doublet with irinotecan combined with aflibercept was administered until progression of disease. The majority of patients received a greater number of aflibercept cycles than the median reported in the VELOUR study (12 vs. 7 cycles), with manageable and reversible toxicity. The most frequent adverse events observed were diarrhoea, neutropenia, fatigue, proteinuria and hypertension. Most cases obtained a progression-free survival greater than the median reported in the VELOUR study (11 vs. 6.9 months) and, in a subgroup of patients previously treated with bevacizumab, and a median survival time of ~47 months was reached from the initial treatment of the disease. The present study contrasts the efficacy and safety results obtained from the pivotal VELOUR trial, and confirms that aflibercept, used in routine clinical practice outside of the clinical trial environment, is active and well-tolerated following bevacizumab treatment.
PB Spandidos Publications
SN 1792-1074
YR 2016
FD 2016-11
LK http://hdl.handle.net/10668/2623
UL http://hdl.handle.net/10668/2623
LA en
NO Alcaide J, Delgado M, Legerén M, Jurado JM, Blancas I, Pereda T, et al. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncol Lett. 2016                         ; 12(5):3127-3134
NO Journal Article;
NO Medical writing assistance, supported financially by Sanofi Spain (Barcelona, Spain).
DS RISalud
RD Apr 19, 2025